Home » Newsletters » BioWorld Science

BioWorld Science

June 8, 2009

View Archived Issues

Astellas Pharma discloses TrkA tyrosine kinase inhibitors for the treatment of urinary conditions

Janssen describes prokineticin-1 receptor antagonists for the treatment of gastrointestinal diseases

Hsp27 inhibitor OGX-427 well tolerated, affects tumor markers in phase I study

AVI BioPharma and CFI sign additional drug development contract for AVI-5038 in DMD

Boehringer Ingelheim discovers phosphodiesterase 4B inhibitors for the treatment of COPD

DSMB recommends continuation of phase III trial comparing Avexa's ATC to 3TC in HIV

Novel sphingosine-1-phosphate receptor agonists described by Pfizer

Novel calcium channel blockers emerge from Pfizer R&D

Belatacept shows immunosuppressant activity in phase II/III studies in kidney transplant recipients

NIAID initiates trial evaluating AEOL-10150 for treating radiation exposure

EyeGate Pharma reports that EGP-437 improves signs and symptoms of dry eye

Pharming receives EMEA agreement on pediatric investigation plan for Rhucin

CNTO-328 shows acceptable safety and promising activity in phase II trials in CRPC and MM patients

Ancora receives phase I SBIR grant from NIH to research SMA vaccine

ACT signs exclusive license for anticancer therapeutic from University of Louisville

Cytopia completes 3-year research term under 2006 collaboration with Novartis

Somaxon resubmits NDA for insomnia drug Silenor to FDA

CDA-1 and CDB-1 show efficacy in phase II study in C. difficile diarrhea

Phase II data on olaparib in breast, ovarian cancer reported at ASCO

Single i.v. dose of BG-9928 displays minimal effect on cardiac conduction in healthy volunteers

Nebivolol does not affect hemoglobin levels in chronic heart failure patients; SENIORS data suggest

Rolofylline fails to demonstrate efficacy for acute heart failure in phase III PROTECT study

PolyMedix initiates dosing in second phase I systemic antibiotic trial

Anadys initiates strategic restructuring to focus on development of ANA-598 in hepatitis C

FDA grants orphan drug designation to Delcath's melphalan for neuroendocrine tumors

Lpath receives grant from the NCI to use for lead candidate Asonep

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for June 16, 2025.
Zusduri flurry ends; ‘set up’ at ODAC, Urogen prevails with FDA
BioWorld
During a conference call after the U.S. FDA approval of Zusduri (mitomycin), Urogen Pharma Ltd. CEO Liz Barrett offered candid observations about a...
23andme founder-led group outbids Regeneron for company
BioWorld
The 23andme Holding Co.’s saga came full circle with founder Anne Wojcicki regaining control of the bankrupt genetic testing company in a bidding battle against...
Elevidys’ second liver death hits Sarepta, sends DMD ripples
BioWorld
How the U.S. FDA might respond became a serious question for Wall Street as Sarepta Therapeutics Inc. made known a second death due to acute liver failure with...